HRS9531 injection for obese adults with moderate-to-severe obstructive sleep apnea who use PAP
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Run by Fujian Shengdi Pharmaceutical Co., Ltd. · NCT06994650 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This trial will test whether HRS9531 injections can reduce sleep apnea events and improve symptoms in adults with obesity and moderate-to-severe OSA who are already using PAP therapy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06994650 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with BMI ≥28 kg/m2, confirmed moderate-to-severe OSA (AHI ≥15 events/hour), on PAP therapy for ≥3 months, and willing to follow study visit and PSG requirements are the ideal candidates.
✕Probably not a fit
People with diabetes, major endocrine causes of weight change, planned or recent major OSA surgery, pregnant or breastfeeding women, or those unwilling to comply with PAP and PSG requirements are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled Phase 3 trial comparing HRS9531 injection with placebo in adults aged 18–75 who have obesity and moderate-to-severe obstructive sleep apnea while on PAP therapy. Participants must have been on PAP for at least three months and will continue PAP overall but may pause it briefly before study sleep tests. Outcomes will include changes in sleep apnea metrics measured by polysomnography and monitoring of safety and adverse events during the treatment period. The multicenter design aims to confirm efficacy and safety seen in earlier development before potential regulatory decisions.
Why it matters
Potential benefit: If successful, HRS9531 could lower apnea-hypopnea events and symptoms, offering an additional treatment option for obese patients already using PAP.
How similar studies have gone: Pharmacologic approaches to OSA have shown modest or mixed results historically, and earlier-phase work for agents like HRS9531 suggested signals that now require confirmation in this larger Phase 3 setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18 -75 (inclusive), male or female Sex 2. BMI ≥28.0 kg/m2； 3. ≥3 months of diet/exercise control pre-screening with ≤5.0 kg weight fluctuation in prior 3 months. 4. Confirmed OSA diagnosis with screening PSG showing AHI ≥15.0 events/h. 5. ≥3 months of PAP therapy pre-screening with planned continuation; willingness to pause PAP ≥1 week before each PSG. 6. Females/males of childbearing potential must use highly effective contraception from consent until 2 months post-treatment, with no pregnancy/donation plans. Females require negative pregnancy test ≤3 days pre-randomization and non-lactating. Exclusion Criteria: 1. Endocrine disorders significantly affecting weight (e.g., Cushing's syndrome, hypo-/hyperthyroidism) or monogenic/hereditary obesity syndromes excluded. 2. Diabetes mellitus (excluding gestational diabetes). 3. Prior/planned OSA-related major surgeries (e.g., tonsillectomy/adenoidectomy) that may affect breathing. 4. Have significant craniofacial abnormalities that may affect breathing at baseline 5. Have diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration 6. Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator. 7. Impaired gastric emptying (e.g., gastric bypass, pyloric stenosis)；Chronic use of GI motility-affecting drugs；Severe GI disorders (e.g., active PUD, IBD)；GI surgeries (except non-motility-affecting procedures) 8. Pancreatic disorders (acute/chronic pancreatitis, pancreatic injury)；Acute cholecystitis history；Symptomatic/treated gallbladder disease 9. Have used drugs or treatments that may cause significant weight gain or loss within 3 months 10. Investigator-determined unsuitability/unwillingness to pause PAP therapy for at least 1 week pre-PSG (e.g., safety/occupational/personal considerations).
Where it's running
-
Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Siai Sun
- Email: siai.sun@hengrui.com
- Phone: 18036618062
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single-dose PK study of HRS-4729 in adults with and without kidney impairment
This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.
-
HRS-4139 safety and pharmacology in healthy adults
This early-phase study tests a single dose of HRS-4139 to see if it is safe and how the body handles it in healthy adults aged 18–55.
-
HRS-7249 extension study for people with high triglycerides
This extension study tests whether repeat injections of HRS-7249 are safe and keep triglyceride levels low in adults who previously completed the parent study or have high fasting triglycerides.
-
HRS5580 plus palonosetron to prevent postoperative nausea and vomiting
This study tests whether HRS5580 given with palonosetron can prevent nausea and vomiting after surgery in adults undergoing certain procedures.
-
HRS9531 tablets vs placebo for weight loss in adults with overweight or obesity
This study tests whether HRS9531 tablets help people who are overweight or obese lose weight over a year, compared with a placebo.
-
HRS-4729 and HRS9531 injections in adults with MASH
This study tests whether HRS-4729 and HRS9531 injections (and their placebos) can help adults with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.